Ping Zhang, Yan Jiang, Chunping Xu, Linghui Zhou, Hongguang Zheng, Deqiong Xie, Minghao Guo, Xiangyang Huang, Guoyuan Lu, Hongli Jiang, Hongyu Qiu, Bicheng Liu, Shaomei Li, Qinkai Chen, Yu'ou Xia, Bengui Sun, Xiao Yang, Shiying Zhang, Shutong Du, Mindan Sun, Menghua Chen, Aimin Zhong, Xiaoling Wang, Zhanzheng Zhao, Hua Zhou, Guisen Li, Yueqin Ren, Qun Luo, Aicheng Yang, Ping Luo, Shuifu Tang, Chengyun Xu, Qin Wang, Xiaoxia Wang, Tiekun Yan, Wei He, Shuguang Qin, Weili Zhang, Lu Lv, Cheng Wang, Hong Liu, Jing Li, Qiong Wu, Chao Pan, Chuan Li, Liangliang He, Jianghua Chen
BACKGROUND: Pegmolesatide, a synthetic peptide-based erythropoietin (EPO) receptor agonist, is being evaluated as an alternative to epoetin alfa for treating anemia of chronic kidney disease (CKD) in Chinese dialysis patients. There is a critical need for a long-acting, cost-effective erythropoiesis-stimulating agent that does not produce EPO antibodies. METHODS: A randomized, open-label, active-comparator, non-inferiority phase three trial was conducted at 43 dialysis centers in China between May 17th, 2019, and March 28th, 2022...
November 2023: EClinicalMedicine